Skip to main content
    N

    NanoViricides Inc (NNVC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.38
    +0.07 (+5.34%)

    Market Cap: $33.44M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    79%(19/24)
    Avg Surprise
    +4.89%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.10+10.0%
    60d ago$-0.10+10.0%
    30d ago$-0.10+10.0%
    7d ago$-0.10+10.0%
    Current$-0.09
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.08
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.080.0%
    60d ago$-0.080.0%
    30d ago$-0.080.0%
    7d ago$-0.080.0%
    Current$-0.08
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.08---
    Sep 26EST
    		-$-0.09---
    Jun 26
    Reported Sep 28
    		$-0.10$-0.11+9.09%Beat+16.7%
    Mar 26
    Reported May 14
    		$-0.09$-0.08-12.50%Miss+35.7%
    Dec 25
    Reported Feb 17
    		$-0.11$-0.08-37.50%Miss+20.9%
    Sep 25
    Reported Nov 14
    		$-0.10$-0.18+44.44%Beat+56.1%
    Jun 25
    Reported Sep 3
    		$-0.12$-0.20+40.00%Beat+36.8%
    Mar 25
    Reported May 15
    		$-0.14$-0.19+26.32%Beat+12.5%
    Dec 24
    Reported Feb 14
    		$-0.14$-0.18+22.72%Beat+22.7%
    Sep 24
    Reported Nov 14
    		$-0.23$-0.17-34.12%Miss-34.1%
    Jun 24
    Reported Sep 27
    		$-0.19$-0.20+5.00%Beat+37.7%
    Mar 24
    Reported May 15
    		$-0.16$-0.19+15.79%Beat-6.7%
    Dec 23
    Reported Feb 14
    		$-0.18$-0.19+5.26%Beat-20.0%
    Sep 23
    Reported Oct 13
    		$-0.17$-0.17+0.00%Beat-21.4%
    Jun 23
    Reported Aug 30
    		$-0.31$-0.17-79.53%Miss-103.5%
    Mar 23
    Reported May 15
    		$-0.15$-0.17+11.76%Beat+6.3%
    Dec 22
    Reported Feb 14
    		$-0.15$-0.16+6.25%Beat+11.8%
    Sep 22
    Reported Oct 13
    		$-0.14$-0.17+17.65%Beat+39.1%
    Jun 22
    Reported Aug 31
    		$-0.15$-0.15+0.00%Beat+16.7%
    Mar 22
    Reported May 17
    		$-0.16$-0.22+27.27%Beat+15.8%
    Dec 21
    Reported Feb 14
    		$-0.17$-0.22+22.73%Beat+22.7%
    Sep 21
    Reported Oct 12
    		$-0.23$-0.20-15.00%Miss-4.5%
    Jun 21
    Reported Sep 1
    		$-0.18$0.00N/ABeat+21.7%
    Mar 21
    Reported May 14
    		$-0.19$0.00N/ABeat+84.7%
    Dec 20
    Reported Feb 16
    		$-0.22$0.00N/ABeat+56.0%
    Sep 20
    Reported Oct 13
    		$-0.22N/AN/ABeat+46.3%
    Jun 20
    Reported Sep 2
    		$-0.23N/AN/ABeat+61.7%
    Mar 20
    Reported Jun 22
    		$-1.24N/AN/ABeat-106.7%
    Dec 19
    Reported Feb 14
    		$-0.50$-0.60+16.67%Beat+16.7%
    Sep 19
    Reported Nov 15
    		$-0.41N/AN/ABeat+31.7%
    Jun 19
    Reported Aug 23
    		$-0.60$-0.80+25.00%Beat-2900.0%
    Mar 19
    Reported May 15
    		$-0.60$-0.60+0.00%Beat-1900.0%
    Dec 18
    Reported Feb 19
    		$-0.60$-0.60+0.00%Beat-1400.0%
    Sep 18
    Reported Oct 12
    		$-0.60N/AN/ABeat-1900.0%
    Jun 18
    Reported Aug 29
    		$-0.02N/AN/ABeat+50.0%
    Mar 18
    Reported May 21
    		$-0.03N/AN/ABeat+40.0%
    Dec 17
    Reported Feb 21
    		$-0.04N/AN/ABeat+92.5%
    Sep 17
    Reported Nov 14
    		$-0.03N/AN/ABeat-
    Jun 17
    Reported Sep 28
    		$-0.04N/AN/ABeat-
    Mar 17
    Reported May 15
    		$-0.05N/AN/ABeat-
    Dec 16
    Reported Feb 14
    		$-0.53N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-3.45EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-101.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.66xQuick Ratio2.66x
    Trading Statistics
    Beta1.79Avg Volume574.26K
    52-Week High$2.2352-Week Low$0.85

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.35
    SMA 20$1.39
    SMA 50$1.31
    SMA 200$1.28
    EMA 10$1.34
    EMA 20$1.34
    EMA 50$1.34
    EMA 200$1.34

    MACD

    Line: 0.01Signal: 0.01Hist: -0.01

    ADX

    ADX: 23.7+DI: 24.5-DI: 17.8

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down12.0
    PSAR$1.46

    Bollinger Bands

    Upper Band$1.61
    Lower Band$1.17
    %B Position3168%(Upper)
    Band Width0.47

    RSI (14-Day)

    Neutral
    52.9

    Momentum Oscillators

    Stoch %K32.3
    Stoch %D23.7
    Williams %R-54.5
    ROC (10d)9.5%
    Momentum0.12
    CCI (20d)-34.2
    MFI (14d)52.4

    Volatility Measures

    ATR (14d)$0.12(8.3%)
    StdDev (20d)0.11
    Hist Vol115.3%(High)

    Volume Flow

    VWAP$1.36
    OBV36.0M
    AD Line-3.9M
    CMF (20d)-0.208

    Volume Metrics

    Avg Vol (20d)493.2K
    Vol Ratio0.4x(Low)
    VWMA (20d)$1.46

    Pivot Points

    R3$1.40
    R2$1.37
    R1$1.34
    Pivot Point$1.31
    S1$1.28
    S2$1.25
    S3$1.22

    Advanced Oscillators

    TSI1.41
    Ultimate Osc39.2
    KST87.62

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/A$0$0$0$161,126$0$0$0$190,603$0$0$0
    Gross ProfitN/A$0$0$0$-161,126$0$0$0$-190,603$0$0$0
    Operating Expenses$2.25M$2.03M$2.23M$1.80M$2.12M$2.25M$2.06M$3.17M$2.39M$1.91M$2.18M$2.03M
    R&D$1.31M$1.29M$1.12M$993,066$1.18M$1.28M$1.16M$1.93M$1.18M$1.21M$1.57M$1.47M
    SG&A$936,316$744,276$1.11M$803,619$938,196$966,905$902,700$1.23M$1.21M$693,742$610,877$564,926
    Operating Income$-2,246,284$-2,030,218$-2,233,174$-1,796,685$-2,115,604$-2,249,156$-2,059,051$-3,167,834$-2,391,361$-1,908,403$-2,184,756$-2,031,591
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$3.11M$0$0$0$1.90M$0$0$36,493
    Income Before Tax$-2,223,399$-1,989,333$-2,220,719$-1,785,058$-5,222,692$-2,216,783$-2,027,491$-3,126,811$-4,288,240$-1,854,476$-2,101,622$0
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,223,399$-1,989,333$-2,220,719$-1,785,058$-2,095,881$-2,216,783$-2,027,491$-3,126,811$-2,355,987$-1,854,476$-2,114,937$-1,968,746
    EBITDA$-2,093,650$-1,859,699$-2,087,636$-1,652,238$-1,934,755$-2,025,600$-1,831,459$-2,931,198$-2,165,384$-1,664,520$-1,912,291$-1,743,129
    EBIT$-2,223,399$-1,989,333$-2,220,719$-1,785,058$-2,095,881$-2,216,783$-2,027,342$-3,126,811$-2,355,987$-1,854,476$-2,101,622$-1,932,253
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NNVC

    News

    Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

    NanoViricides announced that its Phase IIA clinical trial for NV-387 Oral Gummies, a treatment for Ebola Bundibugyo virus...

    ACCESS Newswire•10/13/26•Bullish

    NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

    NanoViricides, Inc. is conducting a Phase II clinical trial for NV-387 Oral Gummies to treat the Bundibugyo Ebolavirus (BDBV) outbreak in the Democratic Republic of Congo. The Phase IIA part focuses on determining...

    The Tennessean•10/10/26•Bullish

    Form DEF 14A NANOVIRICIDES For: 8 October By Investing.com

    This article reports on the filing of Form DEF 14A by Nanoviricides (NNVC) on October 8. It indicates that the company's stock, NNVC...

    Investing.com Nigeria•10/8/26•Neutral

    Form DEF 14A NANOVIRICIDES For: 8 October By Investing.com

    This article announces the filing of Form DEF 14A by NANOVIRICIDES for October 8th. It is a brief report from Investing.com...

    Investing.com UK•10/8/26•Neutral

    NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026

    NanoViricides, Inc. (NYSE American: NNVC) is scheduled to present at NIBA's 153rd Investment Conference in Fort Lauderdale, Florida on October 7...

    Yahoo Finance•10/7/26•Bullish

    NNVC Valuation and Fair Value

    P/E
    -3.5x
    PEG
    0.0x
    P/B
    3.2x
    See GNG's fair value

    NNVC Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -101.5%

    NNVC Competitors

    CompanyTicker
    CryoCell International IncCCEL
    Elutia Inc.ELUT
    CervoMed Inc.CRVO
    China Pharma Holdings IncCPHI
    Genenta Science SpA ADRGNTA
    Quince Therapeutics, Inc.QNCX
    Mural Oncology plcMURA
    Briacell Therapeutics CorpBCTX

    Sector: Healthcare

    NNVC Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    7.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.09
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About NNVC

    Does NNVC pay dividends?

    NanoViricides Inc (NNVC) does not currently pay a regular dividend.

    What is NNVC's market cap?

    NanoViricides Inc (NNVC) has a market capitalization of $33.44M with a current stock price of $1.38.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In